Pulsed Field Ablation for Atrial Fibrillation Trial Reveals Elevated Stroke Risk

2026-04-29 14:41

Favorite

en.Wedoany.com Reported - The AVANT GUARD trial, comparing pulsed field ablation (PFA) with antiarrhythmic drugs (AAD) in patients with persistent atrial fibrillation, showed that PFA is superior to drugs in reducing asymptomatic atrial fibrillation, but its safety outcomes and symptom improvement were disappointing. Conducted by researchers in the United States and North America, the trial enrolled 310 patients randomized to receive treatment with Boston Scientific's Farapulse PFA system (207 patients) or AAD therapy (103 patients).

Wedoany". If there is any infringement or other issues, please notify us promptly, and we will modify or delete it accordingly. Email: news@wedoany.com

America

Healthcare Engineering Medical Instruments and Equipment Engineering

This bulletin is compiled and reposted from information of global Internet and strategic partners, aiming to provide communication for readers. If there is any infringement or other issues, please inform us in time. We will make modifications or deletions accordingly. Unauthorized reproduction of this article is strictly prohibited. Email: news@wedoany.com

Previous：U.S. Serif Launches Modified DNA Therapy with $50M Funding from Flagship Pioneering

Next：Nordic-Baltic Delegation Promotes Smart Transportation in Turkey at Istanbul

Related Recommendations